Question
The Hatch-Waxman Act provides for the safe harbor provision to enable generic drug companies to begin the development of a generic drug before the expiration
The Hatch-Waxman Act provides for the safe harbor provision to enable generic drug companies to begin the development of a generic drug before the expiration of the patented technology of the innovator company. However, it also provides a possible patent extension for the innovator company. Do you think that it strikes the right balance, or do you think that it could have been drafted more advantageously to balance incentives for the innovator companies while also fostering the earlier development of generic drugs? What do you think is the best way to balance these interests?
Step by Step Solution
There are 3 Steps involved in it
Step: 1
Get Instant Access to Expert-Tailored Solutions
See step-by-step solutions with expert insights and AI powered tools for academic success
Step: 2
Step: 3
Ace Your Homework with AI
Get the answers you need in no time with our AI-driven, step-by-step assistance
Get Started